Table 2 Clinicopathologic characteristics according to BRAF mutation status
From: The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
| Â | Patients with BRAF status | p-value | ||
|---|---|---|---|---|
Negative | Positive | Total | ||
(NÂ =Â 1052) | (NÂ =Â 44) | (NÂ =Â 1096) | ||
Sex | Â | Â | Â | 0.149 |
 Male | 652 (62.0%) | 22 (50.0%) | 674 (61.5%) |  |
 Female | 400 (38.0%) | 22 (50.0%) | 422 (38.5%) |  |
Age | Â | Â | Â | 0.375 |
  < 50 year | 131 (12.5%) | 8 (18.2%) | 139 (12.7%) |  |
  ≥ 50 year | 921 (87.5%) | 36 (81.8%) | 957 (87.3%) |  |
Location | Â | Â | Â | 0 |
 Rt colon | 252 (24.0%) | 25 (56.8%) | 277 (25.3%) |  |
 Lt colon | 455 (43.3%) | 14 (31.8%) | 469 (42.8%) |  |
 Rectum | 324 (30.8%) | 4 (9.1%) | 328 (29.9%) |  |
 Multiple | 21 (2.0%) | 1 (2.3%) | 22 (2.0%) |  |
Stage | Â | Â | Â | 0.226 |
 Tis | 23 (2.2%) | 0 (0.0%) | 23 (2.1%) |  |
 StageI | 205 (19.6%) | 5 (11.4%) | 210 (19.2%) |  |
 StageII | 323 (30.9%) | 12 (27.3%) | 335 (30.7%) |  |
 StageIII | 496 (47.4%) | 27 (61.4%) | 523 (47.9%) |  |
T stage | Â | Â | Â | 0.006 |
 T1 | 93 (9.1%) | 3 (6.8%) | 96 (9.0%) |  |
 T2 | 173 (16.9%) | 4 (9.1%) | 177 (16.6%) |  |
 T3 | 637 (62.1%) | 24 (54.5%) | 661 (61.8%) |  |
 T4 | 122 (11.9%) | 13 (29.5%) | 135 (12.6%) |  |
N stage | Â | Â | Â | 0.015 |
 N0 | 553 (52.7%) | 17 (38.6%) | 570 (52.1%) |  |
 N1 | 282 (26.9%) | 10 (22.7%) | 292 (26.7%) |  |
 N2 | 215 (20.5%) | 17 (38.6%) | 232 (21.2%) |  |
M stage | Â | Â | Â | Â |
 M0 | 3 (75.0%) | 0 (0.0%) | 3 (75.0%) |  |
 M1 | 1 (25.0%) | 0 (0.0%) | 1 (25.0%) |  |
Lymphatic invasion | Â | Â | Â | 0.007 |
 Absent | 588 (56.0%) | 15 (34.1%) | 603 (55.1%) |  |
 Present | 462 (44.0%) | 29 (65.9%) | 491 (44.9%) |  |
Venous invasion | Â | Â | Â | 0.109 |
 Absent | 873 (83.2%) | 32 (72.7%) | 905 (82.8%) |  |
 Present | 176 (16.8%) | 12 (27.3%) | 188 (17.2%) |  |
Perineural invasion | Â | Â | Â | 0.451 |
 Absent | 804 (76.6%) | 31 (70.5%) | 835 (76.3%) |  |
 Present | 246 (23.4%) | 13 (29.5%) | 259 (23.7%) |  |
Differentiation | Â | Â | Â | 0.081 |
 Well | 96 (9.5%) | 2 (5.0%) | 98 (9.4%) |  |
 Moderate | 875 (86.9%) | 34 (85.0%) | 909 (86.8%) |  |
 Poor | 36 (3.6%) | 4 (10.0%) | 40 (3.8%) |  |
Histology | Â | Â | Â | 0.302 |
 Non-mucinous adenocarcinoma | 986 (93.7%) | 39 (88.6%) | 1025 (93.5%) |  |
 Mucinous adenocarcinoma | 66 (6.3%) | 5 (11.4%) | 71 (6.5%) |  |
Recur | Â | Â | Â | 0.113 |
 Recur | 894 (85.0%) | 33 (75.0%) | 927 (84.6%) |  |
 Non-recur | 158 (15.0%) | 11 (25.0%) | 169 (15.4%) |  |
Expire | Â | Â | Â | 0 |
 Expire | 956 (90.9%) | 32 (72.7%) | 988 (90.1%) |  |
 Non-Expire | 96 (9.1%) | 12 (27.3%) | 108 (9.9%) |  |
Neoadjuvant Tx | Â | Â | Â | 0.589 |
 No | 929 (88.3%) | 41 (93.2%) | 970 (88.5%) |  |
 CTx | 40 (3.8%) | 2 (4.5%) | 42 (3.8%) |  |
 RT | 2 (0.2%) | 0 (0.0%) | 2 (0.2%) |  |
 CCRT | 81 (7.7%) | 1 (2.3%) | 82 (7.5%) |  |